Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical trial details, royalty milestones, or INPEFA® sales data inside Lexicon Pharmaceuticals’ 200-page reports can feel like its own research project. Biotech disclosures mix dense scientific tables with SEC jargon, and Lexicon Pharmaceuticals insider trading Form 4 transactions often arrive just as new study results hit the wire.
Stock Titan solves the puzzle. Our AI breaks each Lexicon Pharmaceuticals quarterly earnings report 10-Q filing, 8-K update, or proxy into concise, plain-English briefs. Need to spot dose-response outcomes in seconds? Curious how R&D spending shifted before Phase 3? You’ll find answers in our real-time dashboard, along with alerts for Lexicon Pharmaceuticals Form 4 insider transactions real-time. We cover every document type—10-K, 10-Q, 8-K, S-3, DEF 14A—linking them to natural questions investors ask, like “What does Lexicon disclose about LX9211’s safety profile?” or “How is executive compensation tied to FDA milestones?”.
Dive deeper with context you won’t get from EDGAR alone. Our summaries flag where the Lexicon Pharmaceuticals annual report 10-K simplified explains Genome5000™ costs, highlight each Lexicon Pharmaceuticals proxy statement executive compensation table, and translate risk-factor language into actionable insights. Follow Lexicon Pharmaceuticals earnings report filing analysis quarter over quarter, track Lexicon Pharmaceuticals executive stock transactions Form 4, and view every Lexicon Pharmaceuticals 8-K material events explained—all through one interface. If you’re serious about understanding Lexicon Pharmaceuticals SEC documents with AI-assisted clarity, this is your starting line.
On 07/07/2025, FMR LLC – the parent company of Fidelity Investments – and its chair & CEO Abigail P. Johnson filed a Schedule 13G disclosing ownership of 5,600,662 common shares of Omada Health, Inc. (OMDA), corresponding to 10.0 % of the outstanding stock as of the event date 06/30/2025.
The filing indicates a passive investment under Rule 13d-1(b). FMR LLC reports sole voting power and sole dispositive power over the entire position, with no shared voting or dispositive authority. Ms. Johnson is deemed a co-reporting beneficial owner because of her control of FMR LLC; she likewise claims sole dispositive power over the same shares.
No purchase price, transaction details, or intent to influence control are provided. The signatories certify that the shares were acquired in the ordinary course of business and not in connection with any control-changing objective or proxy contest. An exhibit lists the subsidiaries through which the securities are held, but those details are not included in the text provided.
Implications for investors:
- A blue-chip institutional investor now holds a double-digit stake, which can enhance market confidence and liquidity.
- Because the filing is on Schedule 13G, FMR signals a passive stance; however, surpassing the 10 % threshold increases its potential influence in future corporate governance matters if it later opts for an active role.
- The concentration of voting rights in a single institution could also become a risk factor should Fidelity decide to trim or exit the position.
The document contains no financial statements, earnings data, or management commentary; it is strictly an ownership disclosure required by SEC rules.
Lexicon Pharmaceuticals, Inc. (LXRX) disclosed in an 8-K filing that on July 3, 2025 it received written notice from Nasdaq Listing Qualifications granting the company an additional 180-day grace period—until December 30, 2025—to regain compliance with the $1.00 minimum bid-price requirement for continued listing. To secure the extension, Lexicon applied to transfer its shares from the Nasdaq Global Select Market to the Nasdaq Capital Market; Nasdaq has approved the transfer, which will become effective at the opening of trading on July 7, 2025.
During the second compliance period, the company must deliver a closing bid price of at least $1.00 for 10 consecutive business days. Eligibility for the extension remains contingent on meeting all initial Capital Market listing standards—except the bid price—and providing written confirmation that Lexicon intends to cure the deficiency, which may include effecting a reverse stock split if necessary.
The notice prevents an immediate delisting but underlines the ongoing risk that LXRX shares could be removed from Nasdaq if compliance is not restored by year-end. Investors should monitor management’s plans—particularly any potential reverse split—and the stock’s trading performance over the coming months.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
What is Lexicon Pharmaceuticals known for?
How does Lexicon discover its drug candidates?
What are some key therapeutic areas Lexicon is focused on?
What distinguishes Lexicon’s approach in the competitive biopharmaceutical industry?
What is the significance of INPEFA® and LX9211 in Lexicon's portfolio?
How does Lexicon ensure the safety and efficacy of its drug candidates?
How does Lexicon align with E-E-A-T principles?
